|
Frequently Asked Questions
| | Prevention | | What can be done to prevent outbreaks of WNV? | | Is there a vaccine against WNV encephalitis? | | Where can I get information about the use of pesticide sprays that are being used for mosquito control? | | Screening | | What is being done currently to reduce the risk for transfusion-related WNV transmission? | | Should people avoid getting blood transfusions or organ transplants? | | How can blood banks avoid collecting blood from donors who may have WNV? | | Diagnosis | | Is WNV seasonal in its occurrence? | | What proportion of people with severe illness caused by WNV die? | | What are WNV meningitis, WNV encephalitis, and WNV acute flaccid paralysis? | | Consultation for Diagnosis | | Should a neurologic specialist or subspecialist be consulted for diagnosis? | | Should an infectious disease specialist or subspecialist be consulted for diagnosis? | | Hospitalization | | Should patients with encephalitis be hospitalized? | | Should patients with acute flaccid paralysis be hospitalized? | | Should patients with acute flaccid paralysis be sent for physical rehabilitation? | | Non-drug Therapy | | Do patients with WNV encephalitis or other neuroinvasive syndromes need intravenous therapy? | | Do patients with WNV encephalitis or other neuroinvasive syndromes need ventilatory support? | | Do patients with WNV encephalitis or other neuroinvasive syndromes need rehabilitation (either short- and/or long-term)? | | Drug Therapy | | Is ribavirin indicated for treatment of WNV meningitis, encephalitis, or other neuroinvasive syndromes? | | Is acyclovir indicated for treatment of WNV meningitis, encephalitis, or other neuroinvasive syndromes? | | Are corticosteroids indicated for treatment of WNV meningitis, encephalitis, or other neuroinvasive syndromes? | | Patient Education | | Do patients with muscle weakness often require rehabilitation? | | Are there adverse effects to participation in therapeutic trails? | | Consultation for Management | | Should a neurologic specialist or subspecialist be consulted for management? | | Should an infectious disease specialist or subspecialist be consulted for management? | | Should a critical care specialist or subspecialist be consulted for management? | | Should a physiatrist or subspecialist be consulted for management? | | Follow-up | | What have been the residua of WNV encephalitis? | | What have been the residua of WNV acute flaccid paralysis? |
| |
|
Patient Information |
|
Amy V. Bode, MD, MSPH has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Anthony A. Marfin, MD, MPH has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. James J. Sejvar, MD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Nicole Nemeth, DVM, PhD, editorial consultant, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Deborah Korenstein, MD, FACP, Co-Editor, PIER, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Richard B. Lynn, MD, FACP, Co-Editor, PIER, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. |
|
|
|
The information included herein should never be used as a substitute
for clinical judgment and does not represent an official position of
ACP. Because all PIER modules are updated regularly, printed web pages
or PDFs may rapidly become obsolete. Therefore, PIER users should
compare the date of the last update on the website with any printout
to ensure that the information being referred to is the most current
available.
|
PIER is copyrighted © 2012 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.
|
|